Enleofen Bio is a biotechnology company that focuses on developing first-in-class antibody therapeutics for the treatment of fibrotic human diseases. Following the breakthrough discovery in the importance of interleukin 11 as a main driver of fibrosis, Enleofen was founded as a spin-out from National Heart Centre Singapore, SingHealth and Duke-NUS Medical School with Series A funding to translate research findings into treatments that will improve and save the lives of millions of patients worldwide.
We aim to develop our lead antibodies in clinical trials within a two-year time frame with the goal of creating a drug that can be used to treat multiple diseases for which there are currently no treatment options. You can find out more about Enleofen by visiting our website at https://www.enleofen.com/.
Company Details
- Employees
- 2
- Address
- 160 Robinson Road, Sbf Center,#23-02,singapore
- in****@****fen.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- enleofen.com
- Keywords
- Bio-Cumulus International Pte Ltd.
- HQ
- Singapore, Singapore
Enleofen Bio Questions
Enleofen Bio's website is enleofen.com
Enleofen Bio's LinkedIn profile is https://sg.linkedin.com/company/enleofen
Enleofen Bio has
2 employees.
View email and phone details for 2
employees at Enleofen Bio.
Enleofen Bio's industry is
Biotechnology Research
Enleofen Bio's top competitors are
Zero2.5 Biotech Pte Ltd,
Bio-Cumulus International Pte Ltd,
Advanced Bio-Gen,
Bio Eco Innov8 Asia,
Engine Biosciences,
Pairx Bio,
Ybmd,
Carbon 2 Climate,
Outram Bio,
Field Labs.
Enleofen Bio's support email address is info@enleofen.com
Enleofen Bio's categories are Biotechnology Research
